


## Supplemental Information


### Cytoplasmic retention of the DNA/RNA binding protein FUS ameliorates organ fibrosis in mice

Manuel Chiusa<sup>1</sup>, Youngmin A. Lee<sup>2</sup>, Ming-Zhi Zhang<sup>1</sup>, Raymond C. Harris<sup>1,3</sup>, Taylor Sherrill<sup>4</sup>, Volkhard Lindner<sup>5</sup>, Craig R. Brooks<sup>1</sup>, Gang Yu<sup>6</sup>, Agnes B. Fogo<sup>7,1</sup>, Charles R. Flynn<sup>2</sup>, Jozef Zienkiewicz<sup>8,3</sup>, Jacek Hawiger<sup>8,3</sup>, Roy Zent<sup>1,3</sup>, Ambra Pozzi<sup>1,3</sup>




#### Supplemental Figure 1

**Analysis of glomerular phosphorylated EGFR.** (A) Representative images of kidney sections from uninjured (0w) or 8-week ADR-treated WT and *ItgA1KO* mice crossed with *Wave2* mice or treated with erlotinib (ERL) stained with anti-phospho EGFR (red) or DAPI (blue). Scale bar, 15  $\mu$ m. (B) Glomerular red fluorescence staining was evaluated using Image J as described in the Methods and expressed as % of phosphorylated EGFR positive cells/glomerulus. Values are the mean  $\pm$  SD, and symbols represent individual kidneys (n=5 for all genotypes and treatments with an average of at least 10 glomeruli/kidney). Statistical analysis: one-way ANOVA followed by Dunnett's Multiple Comparison Test.




## Supplemental Figure 2

**Expression and localization of human FUSR521G mutant protein.** (A) Genotyping of progeny of *CAG-LacZ<sup>fl/fl</sup>-FUSR521G-IRES-EGFP* mice crossed with *Pdgfrb-cre* mice showing the successful generation of *FUSR521G;Pdgfrb-cre* (*FUSR521G*) positive mice. *FUSR521G* negative for *Cre* or *Cre* mice negative for *FUSR521G* were used as controls for the in vivo experiments performed in this study. (B, C) Kidney paraffin sections (B) or total kidney lysates (C) from control (*Cre* n=4) and *FUSR521G* (n=4) mice were analyzed for GFP localization and expression using selective anti-GFP antibody. Scale bar in (B), 15  $\mu$ m. (D) Representative images of kidney sections from uninjured (*Cre*) or 2-week-ADR-treated *Cre* and *FUSR521G;Pdgfrb-cre* (*FUSR521G*) mice stained with anti-phospho EGFR (red) or DAPI (blue). Scale bar, 15  $\mu$ m. (E) Glomerular red fluorescence staining was evaluated using Image J as described in the Methods and expressed as % of phosphorylated EGFR positive cells/glomerulus. Values are the mean  $\pm$  SD, and symbols represent individual kidneys (*Cre*-0w n=4, *Cre*-2w n=4, *FUSR521G*-2w n=4 with an average of at least 10 glomeruli/kidney). Statistical analysis: one-way ANOVA followed by Dunnett's Multiple Comparison Test (B, D, E).



### Supplemental Figure 3

**Localization of CP-FUS-NLS peptide in kidney and liver.** C57BL/6 J male mice received i.p. injections of vehicle (PBS) or fluorescein amidite (FAM)-conjugated CP-FUS-NLS every two hours for a total of 6 hours. Two hours after the last injection, kidneys and livers were collected. **(A, B)** Representative green fluorescence images of frozen sections of kidneys collected from the mice described above. Note the presence FAM-CP-FUS-NLS peptide in both tubules and glomeruli. Scale bar, 25  $\mu$ m. **(C)** Representative green fluorescence images of frozen sections of livers collected from the mice described above. Positive green staining was detected in the livers of FAM-CP-FUS-NLS-injected mice. CV, central vein. Scale bar, 25  $\mu$ m.



### Supplemental Figure 4

**Murine HSC line J1 responds to EGF treatment.** (A) Total cell lysate (50 µg/lane) of serum-starved J1 cells treated for 1-60 min with EGF (20 ng/ml) were analyzed by Western blot for levels of phosphorylated and total EGFR. (B) Bands were quantified by densitometry analysis and values represent pEGFR/EGFR ratio. Values are the mean ± SD, and symbols represent individual experiments (n=5). Statistical analysis: one-way ANOVA followed by Dunnett's Multiple Comparison Test.